Search tips
Search criteria 


Logo of neuroncolAboutAuthor GuidelinesEditorial BoardNeuro-Oncology
Neuro Oncol. 2008 April; 10(2): 68.
PMCID: PMC2613812

“Review”-ing Our New Opportunities for “Rapid Report”-ing

W. K. Alfred Yung, Editor in Chief

Now that we at Neuro-Oncology are well on our way with our more frequent publication schedule, we would like to take this opportunity to highlight a couple of meaningful opportunities this development presents for enhancing our editorial coverage. Perhaps most obviously, we can now begin to consider and publish Rapid Reports that are truly deserving of the name. In the past, we have used the heading to showcase articles that have undergone expedited review and relatively quick publication. However, in a quarterly journal, there was a built-in delay that no amount of hurrying on the editorial side could make up for.

Now that we have moved to a bimonthly schedule, we anticipate publishing more Rapid Reports and getting critical, time-sensitive information into your hands sooner. We invite those of you who have not considered Neuro-Oncology an appropriate outlet for such articles to rethink that position. Between our increased publication frequency and still-evolving changes that will expedite online posting of accepted papers, Neuro-Oncology combines the best combination of speed and rigorous quality standards for important messages.

Our more frequent publication schedule also makes Neuro-Oncology an attractive venue for important review articles and meta-analyses. This journal is in a unique position, by virtue of its broad reach in terms of geographic and content coverage, to provide timely and comprehensive review articles to the neurooncology community and its affiliates. In the next several issues, you will be treated to review articles on clinical trial design and risks of clinically important short- and long-term sequelae of therapy.

To meet the needs of our diverse readership, we are actively seeking articles in additional topics, from basic science all the way through to end-of-life care. Again, we invite those of you working in the fields of neuro-oncology, neurosurgery, genomics/proteomics, molecular biology, radiation therapy, oncology nursing — in short, all those in our readership community — to consider Neuro-Oncology as your communication tool of choice. If you are considering putting together a review or meta-analysis that may be of interest to your colleagues, please send us a note or call the editorial office. We look forward to hearing your ideas and considering your papers.

Of course, your feedback is always valuable, no matter the topic. In fact, it was your support that made moving from quarterly to bimonthly publication a reality. Thank you for helping provide the impetus for that important step in Neuro-Oncology’s growth. And thank you in advance for helping us use this opportunity to your best advantage.

Articles from Neuro-Oncology are provided here courtesy of Society for Neuro-Oncology and Oxford University Press